An increasing number of case reports and series have linked HLH to PD-1/PD-L1 inhibitors, with combination regimens (e.g., PD-1 plus CTLA-4 blockade) carrying heightened risk. This evidence concerns the gene CD274 and hemophagocytic syndrome.